Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug
August 11, 2021 07:00 ET
|
Akouos, Inc.
BOSTON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
Akouos to Present at Upcoming August Virtual Investor Conferences
August 04, 2021 07:00 ET
|
Akouos, Inc.
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates
May 13, 2021 07:00 ET
|
Akouos, Inc.
- Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer - AK-OTOF granted both Orphan Drug Designation and Rare Pediatric Disease Designation by FDA and is on...
Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy 24th Annual Meeting
May 11, 2021 08:24 ET
|
Akouos, Inc.
- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression...
Akouos Appoints Dr. Kathy Reape as Chief Development Officer
May 07, 2021 07:00 ET
|
Akouos, Inc.
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
Akouos to Present at Bank of America 2021 Virtual Healthcare Conference
May 07, 2021 07:00 ET
|
Akouos, Inc.
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
Akouos to Present Nonclinical Data from AK-OTOF and AK-antiVEGF Programs at the American Society of Gene and Cell Therapy 24th Annual Meeting
April 27, 2021 16:30 ET
|
Akouos, Inc.
BOSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss
April 13, 2021 08:30 ET
|
Akouos, Inc.
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
Akouos to Present at 20th Annual Needham Virtual Healthcare Conference
April 08, 2021 07:00 ET
|
Akouos, Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
Akouos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
March 29, 2021 06:58 ET
|
Akouos, Inc.
- In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF -...